A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?

Surgical Endoscopy, Journal Year: 2024, Volume and Issue: 38(11), P. 6560 - 6565

Published: Sept. 16, 2024

Language: Английский

---

Mitigation of Insulin Resistance, Inflammation, Oxidative Stress, and Metabolic Abnormalities by Bavachalcone in High-Fat/High-Fructose Diet-Fed Rats

Indian Journal of Pharmaceutical Education and Research, Journal Year: 2025, Volume and Issue: 59(1), P. 134 - 143

Published: Jan. 6, 2025

Background Obesity is defined by an excess of body fat, together with insulin resistance and dyslipidemia. These factors significantly elevate the risk acquiring chronic disorders such as Diabetes Mellitus (DM), cardiovascular diseases, neurological disorders, etc. Objectives The goal current study was to evaluate bavachalcone's beneficial effects on obesity in experimental rats fed a High-Fat High-Fructose (HFa-HFr) diet. Materials Methods metabolic complications were induced HFa-HFr diet feeding for period 10 weeks treated bavachalcone from 5th 10th weeks. various parameters food water consumption, weight, insulin, blood glucose level, serum biochemical markers, liver oxidative stress proinflammatory cytokine levels assessed after treatment. Additionally, histopathological examination conducted tissues. Results findings showed that exhibited notable elevation glucose, fat deposits, marker enzyme activities. changes effectively mitigated Furthermore, resulted elevated accumulation, stress, inflammatory biomarker levels. In contrast, treatment successfully reduced resistance, deposition, inflammatory, conditions diet-fed rats. Conclusion results clearly diet-caused abnormalities reducing deposition markers. Keywords: Metabolic syndrome, Fatty liver, Bavachalcone, Insulin Inflammation

Language: Английский

---

Medicinal Plant Extracts against Cardiometabolic Risk Factors Associated with Obesity: Molecular Mechanisms and Therapeutic Targets

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(7), P. 967 - 967

Published: July 21, 2024

Obesity has increasingly become a worldwide epidemic, as demonstrated by epidemiological and clinical studies. may lead to the development of broad spectrum cardiovascular diseases (CVDs), such coronary heart disease, hypertension, failure, cerebrovascular atrial fibrillation, ventricular arrhythmias, sudden cardiac death. In addition there are other cardiometabolic risk factors (CRFs) visceral adiposity, dyslipidemia, insulin resistance, diabetes, elevated levels fibrinogen C-reactive protein, others, all which increase CVD events. The mechanisms involved between obesity mainly include oxidative stress, inflammation, adipokine dysregulation, cause maladaptive structural functional alterations heart, particularly left-ventricular remodeling diastolic dysfunction. Natural products plants provide diversity nutrients different bioactive compounds, including phenolics, flavonoids, terpenoids, carotenoids, anthocyanins, vitamins, minerals, fibers, possess wide range biological activities antihypertensive, antilipidemic, antidiabetic, activities, thus conferring benefits. this review, we discuss main therapeutic interventions using extracts from herbs in preclinical trials with protective properties targeting CRFs. Molecular targets herb plant for prevention treatment CRFs also reviewed.

Language: Английский

---

Star anise (Illicium verum Hook. F.) polysaccharides: Potential therapeutic management for obesity, hypertension, and diabetes

Food Chemistry, Journal Year: 2024, Volume and Issue: 460, P. 140533 - 140533

Published: July 20, 2024

Language: Английский

---

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article

Indian Journal of Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 28(5), P. 445 - 460

Published: Sept. 1, 2024

Obesity is a heterogeneous, complex, and chronic disease that has detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at molecular level have driven development next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain front-runners this rapidly evolving landscape hormone-based AOMs. Two GLP1RAs, namely Liraglutide Semaglutide, been approved by Food Drug Administration (FDA) European Medicine Agency (EMA) for use clinical practice weight loss. Three oral Danuglipron, Orforglipron, are undergoing advanced trials individuals with obesity. Amylin agonist (AMYRA) Cagrilintide, when used alone or combination demonstrated substantial reduction trials. Tirzepatide, dual glucose-dependent insulinotropic polypeptide (GIP) GLP-1 receptors, observed to be associated significant placebo-subtracted 17.8% 72-week randomized controlled trial. Novel approaches targeting glucagon signalling also yielded promising preliminary results. long-acting GLP1R/glucagon (GCGR) agonists, Survodutide, Mazdutide, Pemvidutide, exhibited loss Retatrutide, GLP1R/GCGR/GIPR tri-agonist, -22.1% 48-week phase-II As note caution, long-term data such medications' safety cardiovascular benefits yet ascertained. Our review provides comprehensive overview emerging AOMs, highlighting diversity options might become available near future.

Language: Английский

---

What Is Food Noise? A Conceptual Model of Food Cue Reactivity

Nutrients, Journal Year: 2023, Volume and Issue: 15(22), P. 4809 - 4809

Published: Nov. 17, 2023

As GLP-1 receptor agonists, like semaglutide, emerge as effective treatments for weight management, anecdotal reports from patients and clinicians alike point to a reduction in what has been colloquially termed "food noise", report experiencing less rumination obsessive preoccupation about food. In this narrative review, we discuss concepts used studies investigate human eating behavior that can help elucidate define food noise, particularly cue reactivity. We propose conceptual model summarizes the main factors have shown determine magnitude of reactivity elicited by external internal cues how these affect short- long-term behavioral clinical outcomes. By integrating key research conducted field, Cue-Influencer-Reactivity-Outcome (CIRO) provides framework be future design interpret findings related noise

Language: Английский

---

Timosaponin A3 Induces Anti-Obesity and Anti-Diabetic Effects In Vitro and In Vivo

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2914 - 2914

Published: March 2, 2024

Obesity is a serious global health challenge, closely associated with numerous chronic conditions including type 2 diabetes. Anemarrhena asphodeloides Bunge (AA) known as Jimo has been used to address pathogenic heat such wasting-thirst in Korean Medicine. Timosaponin A3 (TA3), natural compound extracted from AA, demonstrated potential therapeutic effects various disease models. However, its on diabetes and obesity remain largely unexplored. We investigated the anti-obesity anti-diabetic properties of TA3 using vitro vivo treatment NCI-H716 cells stimulated secretion glucagon-like peptide 1 (GLP-1) through activation phosphorylation protein kinase A catalytic subunit (PKAc) 5′-AMP-activated (AMPK). In 3T3-L1 adipocytes, effectively inhibited lipid accumulation by regulating adipogenesis lipogenesis. high-fat diet (HFD)-induced mice model, administration significantly reduced body weight gain food intake. Furthermore, improved glucose tolerance, profiles, mitigated hepatic steatosis HFD-fed mice. Histological analysis revealed that size white adipocytes adipose tissue generation. Notably, downregulated expression lipogenic factor, fatty-acid synthase (FAS) sterol regulatory element-binding 1c (SREBP1c), emphasizing an agent. These findings may be efficiently for tackling obesity, diabetes, metabolic disorders, providing novel approach intervention.

Language: Английский

---

Alvos moleculares dos fármacos utilizados na perda de peso dos pacientes com obesidade

Cuadernos de Educación y Desarrollo, Journal Year: 2025, Volume and Issue: 17(1), P. e7220 - e7220

Published: Jan. 13, 2025

A obesidade é de etiologia complexa e multifatorial, resultando da interação genes, ambiente, estilos vida fatores emocionais. Novos medicamentos para o tratamento envolve uma identificação alvos moleculares específicos que podem ser modulados a influência do peso corporal. O objetivo deste trabalho foi realizar revisão integrativa literatura, analisando fármacos auxiliam no perda paciente com obesidade. Foi realizada busca nas bases dados PubMed Science Direct, utilizando os seguintes descritores idioma inglês: Obesidade, Desenvolvimento Drogas, Ações Farmacológicas, Alvo Terapia, Farmacologia Rede, Terapêutico Receptor. pesquisa resultou na seleção 8 artigos atenderam todos critérios inclusão pesquisa. possível coletar informações respeito diferentes seus mecanismos, dentre eles estão: Receptores Neuropeptídeo Y (NPY), Melanocortina-4 (MC4R), Peptídeo-1 semelhante ao glucagom (GLP-1), Glucagon, Receptor Ativado por Proteinase 2 (PAR2), NMU (NMU-R1 NMU-R2), ácido biliar TGR5 genes TP53, AKT1, MAPK3, PTGS2, TNF, IL6, MAPK1, ERBB2, IL1B MTOR. Concluiu-se desenvolvimento seletivos estes apresenta opções terapêuticas promissoras

---

Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials

Clinical and Translational Science, Journal Year: 2025, Volume and Issue: 18(2)

Published: Feb. 1, 2025

ABSTRACT The effectiveness of glucagon‐like peptide‐1 receptor agonists in facilitating weight loss among patients with diabetes is widely recognized. However, there are limited data available on the relative and safety once‐weekly semaglutide versus once‐daily liraglutide. We conducted a systematic review meta‐analysis randomized controlled trials (RCTs) identified through comprehensive search Cochrane Library, PubMed, ScienceDirect databases from inception until July 2024. Statistical analysis was using R version 4.4.1 “meta” package, employing random effects model. Three RCTs total 922 were included our meta‐analysis. results indicated that OW significantly reduced body (WMD: −4.55; 95% CI: −6.43, −2.67, p < 0.01), HbA1c −0.46; −0.84, −0.08; = 0.02), fasting plasma glucose levels −1.23; −1.51, −0.95; 0.01) comparison to OD risk severe adverse (OR, 1.66; CI, 0.53–5.16; 0.38) gastrointestinal 1.84; 0.82–4.14; 0.14) comparable between both groups. Once‐weekly therapy more pronounced weight, HbA1c, compared

Language: Английский

---

Older Adults’ Views on Insurance Coverage for Weight Management Medications

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(3), P. e252008 - e252008

Published: March 26, 2025

Medicare and many commercial insurers do not cover US Food Drug Administration-approved weight management medications, such as incretin mimetics (semaglutide, tirzepatide, liraglutide), bupropion-naltrexone, phentermine-topiramate). To assess older adults' interest in medications associated characteristics to understand their perceptions about insurance coverage of medications. This survey study used cross-sectional data from a nationally representative sample adults ages 50 80 years the July 2023 National Poll on Healthy Aging. Data were analyzed August November 2023. Outcomes estimates taking medication for by insurers, including Medicare. Among 2657 respondents, 60.3% (95% CI, 56.7%-63.8%) 64 years, 52.2% 49.8%-54.5%) female, 10.6% 9.3%-12.0%) non-Hispanic Black, 11.4% 10.4%-12.6%) Hispanic, 70.3% 68.2%-72.4%) White. Overall, 35.1% 31.9%-38.4%) participants interested using 59.1% 53.4%-64.5%) individuals with body mass index (BMI) 30 or greater. Interest was most robustly having these past (adjusted odds ratio, 7.57 [95% 4.41-13.02]) BMI greater 5.04 3.48-7.30]). Most (of any BMI) agreed that health should (2176 2625 respondents [83.2%]). When asked whether still favored (2097 2616 [75.7%]), but fewer approved paying more premium ensure (829 2604 [30.2%]). In this adults, than half those them. These results inform decisions include programs, well utilization policies control care costs.

Language: Английский

---